Redefining Drug Discovery with Human-Relevant Science
Ethical • Predictive • Personalized
​
Beyond Animal Models. Toward Smarter, Kinder Medicine
Human-Relevant 3D Biology for a Smarter, Kinder Future in Medicine
Inspired by Nature.
Empowered by Technology.
Committed to Life.
At NAMina Bio, science and compassion meet. We integrate advanced 3D biology, organoids, organ-on-chip, and AI-driven analytics to create predictive models that mirror human biology.
Accelerating discovery while reducing animal use.
​
Our mission is to lead the global transition toward ethical, data-driven, and clinically relevant testing systems in alignment with FDA Modernization Act 2.0 and NIH New Approach Methodologies (NAMs).
​
Our Story
​
A Vision Born in the Lab
NAMina Bio was founded on a simple conviction: the future of medicine must be both scientifically advanced and ethically responsible.
After years of studying cancer molecular biology and therapeutic resistance in 3D in vitro systems, our founder, Dr Paola Dama, learned the limits of traditional animal testing and the vast potential of human-based models.
From Research to Revolution
With deep expertise in 3D models, organoids, organ-on-chip platforms, and multi-omics analysis, our team and partners have spent decades perfecting models that truly mirror human biology.
These systems reveal how drugs behave in the body far more accurately than animal experiments ever could: accelerating discovery, improving safety, and reducing cost.
Science with a Soul
NAMina Bio’s name reflects its mission:
NAM for New Approach Methodologies, and ina, from anima: the soul.
For Dr Dama, a lifelong wild-animal rescuer, every life has value. Her compassion for living creatures inspired a company that proves cutting-edge science and empathy can coexist.
Aligned with a New Era
Our work aligns with the FDA Modernization Act 2.0, which officially recognizes non-animal methods for drug testing.
At last, science and regulation are moving together, opening the door to a future where human-relevant models replace animal experiments.
A Dream Realized
NAMina Bio stands at the crossroads of innovation and conscience.
We unite technology, AI-driven analytics, and human-based biology to create a more predictive, humane path for drug discovery.
What began as a dream is now a movement, one that mirrors the momentum of history itself.
Healing Without Harm
Our story is more than a company origin; it’s a commitment:
-
to heal without harm,
-
to innovate without cruelty,
-
and to shape a world where compassion drives discovery.
​
Partnerships & CRO Network Northeast USA
Accelerating Translational Innovation Through Strategic Alliances NAMina Bio bridges academia, biotech, and technology innovators to advance human-based preclinical research. We are actively building a collaborative network of partners across the Northeast USA, establishing NAMina Bio as a regional CRO reference site for companies seeking to enter or expand within the U.S. market. As a Contract Research Organization (CRO), NAMina Bio provides advanced preclinical testing and translational research services grounded in New Approach Methodologies (NAMs) — integrating 3D models, patient-derived organoids, synthetic matrices, organ-on-chip systems, and AI-driven analytics to model human biology with unprecedented precision. From drug discovery and efficacy testing to toxicology, immunomodulation, and mechanistic studies, we help biopharma, biotech, and academic institutions develop safer and more predictive therapies while reducing reliance on animal models. Our partnerships extend across: Biotech & Pharma Companies seeking translational validation and mechanistic insights. Academic Institutions advancing precision medicine and organoid-based models. Technology Providers & Distributors in organ-on-chip, synthetic matrix, and 3D bioprinting platforms. Regional Innovation Hubs and incubators promoting ethical and high-throughput research. Strategically located in the Northeast corridor (NY, NJ, MA, CT, PA), NAMina Bio serves as a reference point for human-based preclinical research, connecting global innovators with the U.S. biomedical ecosystem. We provide a gateway for technology validation, regulatory alignment, and market expansion through our NAM-based testing platforms. Interested in collaborating? We welcome inquiries from research groups, startups, and industry partners to explore joint R&D projects, co-development programs, and platform validation studies.
Join us in shaping the future of drug discovery
Biotech & Pharma
NAMina Bio provides preclinical CRO services using NAMs (human-relevant models) and AI analytics to accelerate discovery, evaluate efficacy, and reduce attrition risk.
Technology Partners
We integrate and validate advanced synthetic matrices, innovative organ-on-chip, bioprinting, and AI-driven systems as regional CRO reference sites for next-generation drug discovery.
Academic Collaborators
We collaborate on grants, translational projects, and training in next-generation 3D and computational models, bridging basic research and precision medicine.
Our Research & Innovation Goals
Redefining Human-Based Research
At NAMina Bio, we are pioneering a new generation of human-relevant models designed to replace outdated animal testing with ethical, predictive, and data-driven systems.
​
Our R&D program brings together 3D biology, AI-driven analytics, and organ-on-chip technologies to build the next frontier in precision drug discovery.
Our goal: To make drug development faster, safer, and truly human-centred, where every model reflects the complexity and beauty of living biology.
Our Vision
We are building a transdisciplinary research ecosystem where biology, technology, and compassion meet.
​
Our R&D aims to deliver a predictive platform that:
​
-
Accelerates discovery
-
Reduces animal use
-
Improves human safety and precision
At NAMina Bio, we believe the future of medicine lies in a simple truth: Healing without harm.
Next-Generation 3D Models
We aim to create tumor-specific 3D systems that reproduce the intricate architecture, mechanics, and signaling found in human tissues.
-
Glioma-on-Chip
​​
We are developing glioma microphysiological systems that replicate the tumour–microenvironment dialogue, including oxygen gradients and neural-vascular signalling.
These models will allow realistic testing of radiotherapy, immunotherapy, and hypoxia-targeted treatments, narrowing the gap between preclinical discovery and real-world outcomes.
-
PDAC Tumoroid Models
Using Inventia Life Science’s RASTRUM™ 3D bioprinting and Real Research’s 3DLife Hydrogel, we are developing pancreatic ductal adenocarcinoma (PDAC) models that mimic native tissue stiffness and drug response.
Our long-term goal is to generate “tumoroids” that reveal adaptive resistance and transporter dynamics, offering a new lens on drug efficacy in complex tumours.
AI-Powered Discovery
Through our collaboration with KolateAI, we are combining biology and computation to unlock the predictive power of data.
By integrating molecular, phenotypic, and clinical datasets, our research aims to build algorithms that:
-
Predict drug–response signatures
-
Optimize experimental design
-
Guide translation from bench to bedside
Our approach: turning complexity into clarity through intelligent data interpretation.
Our Technology Partners
Global partners united under one mission: science without sacrifice.
​
​
​
​
​
​
​
​
​Together, we are building the future of human-relevant drug discovery.
NAMina Bio collaborates with leading innovators in biotechnology, bioprinting, and AI-driven analytics.
Each partnership strengthens our mission to replace animal models with data-driven, predictive human systems that redefine biomedical research.
Inventia Life Science
RASTRUM™ is a high-throughput 3D bioprinting platform that enables rapid, reproducible generation of complex cell models for drug discovery, cancer research, and translational biology. The platform combines biofabrication precision with scalable, automated workflows to bridge the gap between bench biology and therapeutic outcomes.
RASTRUM™ is used by academic, biotech, and pharmaceutical researchers worldwide to create phenotypically relevant 3D models that better predict human response and reduce reliance on animal testing.
Real Research
Advanced 3D Biomaterials and Patient-Derived Models
Real Research’s 3DLife Hydrogels provide customizable matrices that support the growth of complex, physiologically relevant 3D model systems for translational studies.
KolateAI
AI-Driven Multi-Omics Integration for Precision Prediction
KolateAI’s computational platform merges molecular, phenotypic, and clinical data to identify drug-response signatures and optimise bench-to-bedside translation.
Innovation with Purpose
Every model we create moves science forward, away from reliance on animals and toward true human relevance.
NAMina Bio stands for innovation with integrity, uniting compassion, computation, and cellular intelligence to build the next era of biomedical discovery: a world where healing begins with humanity.
​
Together with our partners, we form a synergistic ecosystem aligned with the FDA Modernization Act 2.0 and global New Approach Methodologies (NAMs), driving the future of ethical, predictive, and human-based research.